Dina Ben Yehuda

Jerusalem, JM 91120, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

CD74-Targeted Cathepsin-Inhibitor Antibody-Drug Conjugate Triggers Apoptosis in DLBCL.

CD74-Targeted Cathepsin-Inhibitor Antibody-Drug Conjugate Triggers Apoptosis in DLBCL.

Journal: Cells

Published: December 09, 2025

European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.

European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.

Journal: British journal of haematology

Published: June 19, 2025

Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death.

Doxorubicin-Loaded Nanoparticle Treatment Enhances Diffuse Large B-Cell Lymphoma Cell Death.

Journal: Cells

Published: May 26, 2025

AI-BASED HEALTH AND BIOLOGICAL SCIENCES: AN OPPORTUNITY FOR ISRAELI LEADERSHIP

AI-BASED HEALTH AND BIOLOGICAL SCIENCES: AN OPPORTUNITY FOR ISRAELI LEADERSHIP

Journal: Harefuah

Published: November 13, 2024

Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.

Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.

Journal: European journal of haematology

Published: January 07, 2023

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 04, 2023

THE TIME HAS COME! COMPLEMENTARY MEDICINE IN MEDICAL TRAINING IN ISRAEL

THE TIME HAS COME! COMPLEMENTARY MEDICINE IN MEDICAL TRAINING IN ISRAEL

Journal: Harefuah

Published: November 14, 2019

American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City.

American Funding Cutback to East Jerusalem Hospitals: A Blow to the Health of the City.

Journal: American journal of public health

Published: November 08, 2018

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Journal: Nature medicine

Published: July 06, 2018

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.

Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.

Journal: European journal of haematology

Published: February 08, 2018

Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.

Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.

Journal: Hematological oncology

Published: October 28, 2017

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Journal: Haematologica

Published: April 10, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026